<unk>  is a genetically targeted enzyme replacement therapy being studied for use in patients with severe heart failure. It is designed to increase the level of SERCA2a, a sarcoplasmic endoplasmic reticulum calcium (Ca2+) ATPase found in the membrane of the sarcoplasmic reticulum (SR). The SERCA2a gene is delivered to the heart via an adeno-associated viral vector. Using the α-myosin heavy chain gene promoter in the cardiac muscle cells, also called cardiomyocytes,<unk>  is able to direct the gene expression only to the heart muscle.<unk>  is being tested in a phase 2 study, in which has been compared to a placebo in 39 advanced heart failure patients. Thus far, patients treated with<unk>  have shown a 52% reduction in the risk of worsening heart failure compared to patients treated with the placebo.
Mydicar
Earwax
Pannus
Tear gas
Caphosol
Drusen
Snuff 
Pustular bacterid